Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.60 USD
-0.10 (-5.88%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.59 -0.01 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
Ocugen, Inc. [OCGN]
Reports for Purchase
Showing records 61 - 80 ( 122 total )
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Has Another Bridge To Cross - U.S. IND Placed on Clinical Hold
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN EUA Submitted; OCU400 to Enter Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - Programs Progressing With Critical Regulatory Updates Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
EUA for COVAXIN Submitted for Pediatrics Following WHO Granting of EUL
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Shows Favorable Safety of Inhaled Voriconazole In Asthmatics
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN''s Phase 3 Bridging Study IND Submitted - Waiting On FDA''s Feedback
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data for OCU410 Showed Strong Proof-of-Concept in Dry AMD
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Positive COVAXIN Phase 3 Final Readout; Eyes on Health Canada; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update- Focus Still on COVAXIN, but OCU400 to Enter Clinic by YE2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Final Phase 3 Results for COVAXIN Reaffirms Positive Interim Analysis
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Covaxin Regulatory Strategy Altered to BLA; Lower $10.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S